GSMA Partnership Programme Expands to Create the Largest IoT Community in Asia Pacific
25.9.2019 08:00:00 EEST | Business Wire | Press release
The GSMA APAC IoT Partnership Programme has expanded to include more than thirty mobile operators making it the largest IoT community in the Asia Pacific region (APAC), the GSMA announced today. The programme brings operators and their partners together including developers, manufacturers and system integrators to share best practice, discuss challenges and progress updates on the development of IoT across the region. The initiative has seen 7 operators open 9 new IoT Labs in the region to help develop new IoT-based solutions. APAC has the largest IoT market in the world and is expected to reach 11 billion connections by 2025 and be worth $386 billion, according to GSMA Intelligence.
“The programme has doubled in size in less than a year and that is testament to the support, engagement and commitment of the mobile operator community who are collaborating closely with their partners to lead the expansion and growth of IoT across the region,” said Julian Gorman, Head of Asia Pacific, GSMA. “This is now the largest cross-regional IoT community in the world and we are already seeing the impact it is having in terms of the development of new solutions. I look forward to seeing how it continues to grow in the coming years.”
APAC Impact
Since launch in October 2018, the APAC IoT Partnership Programme has had an instant impact throughout the region, encouraging more than 120 companies such as IoT developers or solutions companies to work with operators. The programme has also supported the development, design and funding of 9 new IoT Labs throughout the region that is encouraging the development of new products. The IoT labs are a key mechanism for collaboration, encouraging the joint development of new use cases, services and applications that are enabling IoT innovations to be effectively deployed. The programme has also held a series of workshops exploring key industry topics such as Mobile IoT, AI and 5G as well as offered capacity building for local regulators and stakeholders and provided best practice support.
Mobile IoT Experiencing Fastest Global Growth
The APAC region is the fastest growing IoT market in the world, accounting for approximately 40 per cent of the total global IoT spend in 2018. Global Low Power Wide Area (LPWA) or Mobile IoT network connections have also been driven primarily by the APAC region accounting for nearly 97% of all NB-IoT connections according to ABI Research. Mobile IoT networks are being merged into 5G standards to support low latency, massive IoT and large bandwidth. Thirty-seven of the world’s 119 Mobile IoT networks are also deployed in Asia Pacific across 15 countries. China in particular has been a key market in driving early adoption, accounting for 40 per cent of the global LPWA connections in 2018.
IoT @ GSMA Mobile 360 – Digital Societies
The GSMA IoT programme will host a number of different activities at GSMA M360 – Digital Societies held in Kuala Lumpur on Thursday 26 September 2019. This includes the APAC IoT Innovation Summit which provides attendees with insight from mobile operators and their partners on the latest developments in Mobile IoT. There will also be a number of interactive demos showcasing Mobile IoT, 5G, AI, Big Data Analytics, Blockchain and Drones at IoT Expo – Connected APAC. This will include hands on demonstrations from key industry verticals such as agriculture, aviation and retail and host smart home, smart traffic and smart poultry solutions. For further information, please go here: https://www.gsma.com/iot/events/m360-apac-iot-summit/#expo
The Birth of Beyond Connectivity
The GSMA will launch the ‘Beyond Connectivity’ campaign at Mobile 360 – Digital Societies. Beyond Connectivity describes how mobile operators are delivering innovation and transformative solutions to customers across big data, machine learning, analytics, edge computing and distributed ledger technologies and delivering beyond just data connectivity. To find out more, please go to: www.gsma.com/BeyondConnectivity
-ENDS-
Notes to Editors
- Operators include Axiata Group (Axiata Robi, Celcom, Dialog Axiata, Ncell, Smart Axiata, XL Axiata and Xpand), Indosat Ooredoo, Jazz, M1, Maxis, Mobitel, Smartfren, Singtel Group (Singtel, Optus), StarHub, Telenor Group (Digi, DTAC, Grameenphone, Telenor Connexion, Telenor Myanmar, Telenor Pakistan), Telstra, TM ONE, True, Rakuten, Viettel Group (Metfone, Mytel, Unitel, Viettel), Vodafone Idea
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005080/en/
Contact information
For the GSMA
Gearóid Cashman
+44 79 7679 0169
GCashman@webershandwick.com
GSMA Press Office
pressoffice@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
